Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedJan 13, 2026
DataAggregated Company Financials
Companies69
  • 7D2.3%
  • 3M-20.4%
  • 1Y-4.6%
  • YTD5.0%

Over the last 7 days, the Healthtech industry has risen 2.3%, driven by gains from Veeva Systems of 5.4%. In the past year, the industry is down 4.6%. As for the next few years, earnings are expected to grow by 22% per annum.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 14 Jan 2026US$67.3bUS$13.6b-US$102,102,340.0052.4x-659.3x5x
Fri, 12 Dec 2025US$65.1bUS$13.6b-US$100,808,271.0055.9x-645.8x4.8x
Sun, 09 Nov 2025US$76.5bUS$13.1b-US$23,492,903.0061.6x-3258.4x5.9x
Tue, 07 Oct 2025US$82.8bUS$13.1b-US$211,110,296.0060.7x-392.2x6.3x
Thu, 04 Sep 2025US$76.5bUS$13.2b-US$285,313,296.0054.8x-268.3x5.8x
Sat, 02 Aug 2025US$77.0bUS$13.3b-US$582,741,447.0058.9x-132.1x5.8x
Mon, 30 Jun 2025US$78.9bUS$13.2b-US$1,382,394,447.0055.4x-57.1x6x
Wed, 28 May 2025US$67.1bUS$13.1b-US$1,464,889,073.0053x-45.8x5.1x
Fri, 25 Apr 2025US$66.6bUS$13.2b-US$1,417,865,959.0052.5x-47x5.1x
Sun, 23 Mar 2025US$70.6bUS$13.2b-US$1,405,690,435.0058.7x-50.2x5.4x
Tue, 18 Feb 2025US$77.2bUS$12.9b-US$1,604,881,514.0064.4x-48.1x6x
Thu, 16 Jan 2025US$64.5bUS$12.9b-US$1,638,075,364.0054.2x-39.4x5x
Sat, 14 Dec 2024US$68.9bUS$12.9b-US$1,644,592,390.0055.8x-41.9x5.4x
Mon, 11 Nov 2024US$69.3bUS$12.8b-US$1,677,294,370.0061.7x-41.3x5.4x
Wed, 09 Oct 2024US$63.0bUS$14.0b-US$3,264,827,208.0052.8x-19.3x4.5x
Fri, 06 Sep 2024US$65.3bUS$14.0b-US$3,301,808,821.0056.2x-19.8x4.7x
Sun, 04 Aug 2024US$57.8bUS$13.7b-US$3,169,950,669.0051.8x-18.2x4.2x
Tue, 02 Jul 2024US$56.7bUS$13.7b-US$1,909,009,047.0047x-29.7x4.1x
Thu, 30 May 2024US$57.8bUS$12.7b-US$1,885,422,856.0046.1x-30.7x4.5x
Sat, 27 Apr 2024US$57.2bUS$12.7b-US$1,631,005,679.0046.2x-35.1x4.5x
Mon, 25 Mar 2024US$64.4bUS$14.3b-US$1,502,658,316.0050.1x-42.9x4.5x
Wed, 21 Feb 2024US$64.3bUS$13.8b-US$5,661,107,794.0054x-11.4x4.7x
Fri, 19 Jan 2024US$72.3bUS$18.3b-US$5,780,316,752.0058.1x-12.5x3.9x
Sun, 17 Dec 2023US$68.9bUS$18.3b-US$5,781,192,665.0056.7x-11.9x3.8x
Tue, 14 Nov 2023US$62.3bUS$18.2b-US$5,939,477,037.0049.4x-10.5x3.4x
Thu, 12 Oct 2023US$72.3bUS$18.0b-US$5,559,240,965.0053x-13x4x
Sat, 09 Sep 2023US$75.2bUS$18.0b-US$5,515,729,389.0053.9x-13.6x4.2x
Mon, 07 Aug 2023US$77.2bUS$17.9b-US$5,602,320,123.0058.3x-13.8x4.3x
Wed, 05 Jul 2023US$76.3bUS$17.7b-US$8,580,469,318.0062.1x-8.9x4.3x
Fri, 02 Jun 2023US$74.8bUS$17.7b-US$8,580,932,209.0060.7x-8.7x4.2x
Sun, 30 Apr 2023US$73.5bUS$17.5b-US$8,375,483,855.0059.2x-8.8x4.2x
Tue, 28 Mar 2023US$72.3bUS$17.7b-US$15,395,662,854.0055x-4.7x4.1x
Thu, 23 Feb 2023US$72.2bUS$17.6b-US$10,822,510,563.0053.2x-6.7x4.1x
Sat, 21 Jan 2023US$70.0bUS$17.5b-US$10,803,491,310.0045.1x-6.5x4x
Price to Earnings Ratio

-6.5x


Total Market Cap: US$70.0bTotal Earnings: -US$10,803,491,310.00Total Revenue: US$17.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -99.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the American Healthcare Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 8.1% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.88%
Healthcare1.12%
Healthtech2.30%
Healthtech2.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HTFL HeartFlowUS$32.072.9%
+US$76.6m		n/aPS16.9x
SOPH SOPHiA GENETICSUS$5.259.4%
+US$30.5m		55.3%PS4.9x
SLP Simulations PlusUS$19.873.1%
+US$12.1m		-30.9%PS5.1x
CTEV ClaritevUS$32.422.2%
+US$11.7m		116.1%PS0.6x
TBRG TruBridgeUS$21.951.2%
+US$3.8m		3.2%PE91.2x

Latest News

CTEV
US$32.42
Claritev
7D
2.2%
1Y
116.1%
DOCS
US$41.36
Doximity
7D
-9.5%
1Y
-18.5%
PHR
US$16.58
Phreesia
7D
-3.8%
1Y
-36.5%
SOPH
US$5.25
SOPHiA GENETICS
7D
9.4%
1Y
55.3%
TDOC
US$6.99
Teladoc Health
7D
-12.6%
1Y
-25.3%
WAY
US$30.58
Waystar Holding
7D
-6.0%
1Y
-18.1%
HSTM
US$22.03
HealthStream
7D
-4.8%
1Y
-30.0%

HSTM: Share Buybacks And M&A Activity Will Support Future Upside

Analysts have trimmed their fair value estimate for HealthStream from US$28 to about US$25. They cite updated assumptions on discount rates, revenue growth, profit margins, and a lower future P/E multiple in their refreshed models.
VEEV
US$228.49
Veeva Systems
7D
-3.9%
1Y
8.4%

VEEV: Roche Expansion And CRM Migrations Will Support Durable Premium Outlook

Analysts have trimmed their fair value estimate for Veeva Systems by about US$1 to US$310.98, reflecting modest adjustments to discount rate and growth assumptions while still pointing to what they see as durable growth drivers such as pharma CRM migrations, broader Vault adoption and newer areas like Crossix and AI. Analyst Commentary Recent Street research on Veeva Systems reflects a mix of optimism and caution, with differing views clustering around the durability of growth in CRM and Vault, the timing of pharma migrations, and how current valuation stacks up against execution and contract wins.
TBRG
US$21.95
TruBridge
7D
1.2%
1Y
3.2%

TBRG: Revenue Cycle Realignment And EHR Stability Will Require Steady Execution

Narrative Update The analyst price target for TruBridge now centers around US$23, a modest lift from the prior US$22.60. Analysts point to the potential of the Revenue Cycle Management opportunity alongside a steadier Electronic Health Records business, while still flagging execution risk after recent periods of low growth.
HCAT
US$2.40
Health Catalyst
7D
0.8%
1Y
-59.3%

HCAT: Cautious Sector Reset Will Still Support Future Revenue Visibility

Analysts have reduced their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions on revenue growth and margins, while maintaining a neutral stance on the stock. Analyst Commentary Bullish analysts are framing the lower US$2.75 price target as a recalibration rather than a shift in overall stance, with the neutral rating indicating that they see the current share price as broadly in line with their updated expectations.
CERT
US$9.15
Certara
7D
-4.4%
1Y
-14.8%

CERT: Biosimulation Expansion And New CEO Should Support Shares Rebound

Analysts have trimmed their average price target on Certara by about $0.17 to roughly $12.38. This reflects recent cuts to some individual targets alongside continued recognition of the company as a leader in biosimulation and expectations that prior stock weakness tied to bookings, biopharma budget timing, and leadership changes may have been overdone.
SLP
US$19.87
Simulations Plus
7D
3.1%
1Y
-30.9%
SDGR
US$18.31
Schrödinger
7D
-2.6%
1Y
-4.0%
CCLD
US$2.93
CareCloud
7D
0.3%
1Y
4.6%

CCLD: Cost Controls And New AI Offering Will Support Future Upside

Narrative Update on CareCloud Analysts have lifted their price target on CareCloud to $3.25 from $2.25, citing updated forecasts for revenue growth, a different margin profile, a higher assumed future P/E multiple, and recent Street research that includes new coverage and refreshed estimates following the Q3 report. Analyst Commentary Recent Street research on CareCloud offers a mixed picture, with some upbeat coverage alongside more cautious views.
HTFL
US$32.07
HeartFlow
7D
2.9%
1Y
n/a
SCNX
US$0.54
Scienture Holdings
7D
2.7%
1Y
-87.0%